US206877A
(en)
*
|
|
1878-08-13 |
|
Improvement in paper-pulp washers |
JPS5328173A
(en)
|
1976-08-06 |
1978-03-16 |
Zenyaku Kogyo Kk |
Novel phenylmethanenitro compound and its preparation
|
US4138397A
(en)
|
1978-02-27 |
1979-02-06 |
Richardson-Merrell Inc. |
6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
JPS61103861A
(ja)
|
1984-10-27 |
1986-05-22 |
Nitto Kasei Kk |
アリ−ル置換シアン酢酸エステルの製造方法
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
US5716981A
(en)
|
1993-07-19 |
1998-02-10 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic compositions and methods of use
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
US5510379A
(en)
|
1994-12-19 |
1996-04-23 |
Warner-Lambert Company |
Sulfonate ACAT inhibitors
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
JPH10213820A
(ja)
|
1997-01-31 |
1998-08-11 |
Canon Inc |
液晶素子及び液晶装置
|
WO1998047868A1
(en)
|
1997-04-18 |
1998-10-29 |
Smithkline Beecham Plc |
Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
|
CN1295227C
(zh)
|
1997-06-21 |
2007-01-17 |
罗赫诊断器材股份有限公司 |
具有抗转移和抗肿瘤活性的巴比土酸衍生物
|
ES2287971T3
(es)
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
CN1283995A
(zh)
|
1997-12-11 |
2001-02-14 |
生化制药有限公司 |
抗病毒化合物
|
US6426331B1
(en)
|
1998-07-08 |
2002-07-30 |
Tularik Inc. |
Inhibitors of STAT function
|
AUPP609198A0
(en)
|
1998-09-22 |
1998-10-15 |
Curtin University Of Technology |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
DK1394150T3
(da)
|
1999-02-24 |
2011-03-21 |
Hoffmann La Roche |
4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
|
JP2003509429A
(ja)
|
1999-09-10 |
2003-03-11 |
ノボ ノルディスク アクティーゼルスカブ |
タンパク質チロシンホスファターゼ(ptpアーゼ)のモジュレーター
|
AU6985300A
(en)
|
1999-09-10 |
2001-04-17 |
Novo Nordisk A/S |
Modulators of protein tyrosine phosphatases (ptpases)
|
AUPQ288499A0
(en)
|
1999-09-16 |
1999-10-07 |
Biota Scientific Management Pty Ltd |
Antiviral agents
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
IT1315267B1
(it)
|
1999-12-23 |
2003-02-03 |
Novuspharma Spa |
Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
|
JP2003520042A
(ja)
|
2000-01-24 |
2003-07-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
DE10038019A1
(de)
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Substituierte Triazolopyrid(az)ine
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6562989B2
(en)
|
2000-08-07 |
2003-05-13 |
Yale University |
Catalyst for aromatic C—O, C—N, and C—C bond formation
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
AR030357A1
(es)
|
2000-08-18 |
2003-08-20 |
Lundbeck & Co As H |
Derivados 4 -, 5 -, 6 - y 7-indol
|
HU230302B1
(hu)
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
GB0102109D0
(en)
|
2001-01-26 |
2001-03-14 |
Syngenta Ltd |
Chemical process
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
CN1533400A
(zh)
|
2001-04-10 |
2004-09-29 |
����˹̩����ҩ��˾ |
用于药物发现的探针、系统和方法
|
US6982274B2
(en)
|
2001-04-16 |
2006-01-03 |
Eisai Co., Ltd. |
1H-indazole compound
|
IL158516A0
(en)
|
2001-06-28 |
2004-05-12 |
Pfizer Prod Inc |
Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
|
JP4558314B2
(ja)
|
2001-07-20 |
2010-10-06 |
ベーリンガー インゲルハイム (カナダ) リミテッド |
ウイルスポリメラーゼインヒビター
|
AUPR738301A0
(en)
|
2001-08-30 |
2001-09-20 |
Starpharma Limited |
Chemotherapeutic agents
|
EP1446115B1
(en)
|
2001-11-13 |
2008-02-27 |
Merck Frosst Canada Ltd. |
Cyanoalkylamino derivatives as protease inhibitors
|
CN1612866A
(zh)
|
2001-11-14 |
2005-05-04 |
特瓦制药工业有限公司 |
无定形和结晶形的氯沙坦钾及其制备方法
|
AU2002351748B2
(en)
|
2001-12-21 |
2009-07-09 |
Novo Nordisk A/S |
Amide derivatives as GK activators
|
US7074805B2
(en)
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US20030158188A1
(en)
|
2002-02-20 |
2003-08-21 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
AU2003228744A1
(en)
|
2002-04-29 |
2003-11-17 |
The Ohio State University |
Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
|
WO2004002481A1
(en)
|
2002-06-27 |
2004-01-08 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
EP1541563A4
(en)
|
2002-07-10 |
2007-11-07 |
Ono Pharmaceutical Co |
ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
US20060083784A1
(en)
|
2002-08-07 |
2006-04-20 |
Smithkline Beecham Corporation |
Amorphous pharmaceutical compositions
|
KR20050057408A
(ko)
|
2002-09-18 |
2005-06-16 |
오노 야꾸힝 고교 가부시키가이샤 |
트리아자스피로[5.5]운데칸 유도체 및 이를 유효 성분으로하는 약제
|
AU2003277162C1
(en)
|
2002-09-30 |
2009-12-24 |
The Regents Of The University Of California |
Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
|
JP2004131393A
(ja)
|
2002-10-08 |
2004-04-30 |
Kowa Co |
易溶出性製剤
|
JP2006505571A
(ja)
|
2002-10-15 |
2006-02-16 |
リゲル ファーマシューテイカルズ、インコーポレイテッド |
置換されたインドール及びhcv阻害剤としてのその使用
|
FR2846327B1
(fr)
|
2002-10-25 |
2006-03-24 |
Merck Sante Sas |
Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
|
JP2006513159A
(ja)
|
2002-11-01 |
2006-04-20 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
|
DE50309381D1
(de)
|
2002-11-02 |
2008-04-24 |
Sanofi Aventis Deutschland |
Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
|
DE10251019A1
(de)
|
2002-11-02 |
2004-05-19 |
Aventis Pharma Deutschland Gmbh |
Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
|
US20040146941A1
(en)
|
2002-11-04 |
2004-07-29 |
Biliang Zhang |
Chemical encoding technology for combinatorial synthesis
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
DE10300017A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Selektive MMP 13 Inhibitoren
|
ES2387803T3
(es)
|
2003-01-08 |
2012-10-02 |
Novartis Vaccines And Diagnostics, Inc. |
Agentes antibacterianos
|
US6933311B2
(en)
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
DE602004024375D1
(de)
|
2003-02-14 |
2010-01-14 |
Glaxo Group Ltd |
Carboxamidderivate
|
DE10306941A1
(de)
|
2003-02-18 |
2004-08-26 |
Merck Patent Gmbh |
Benzofuranoxyethylamine
|
EP1601657A1
(en)
|
2003-03-12 |
2005-12-07 |
Vertex Pharmaceuticals Incorporated |
Pyrazole modulators of atp-binding cassette transporters
|
DE10315377A1
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Carbonylverbindungen
|
WO2004087646A2
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
|
US20050164951A1
(en)
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
SI3549936T1
(sl)
|
2003-04-11 |
2021-09-30 |
Ptc Therapeutics, Inc. |
Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
|
ATE482747T1
(de)
|
2003-04-11 |
2010-10-15 |
High Point Pharmaceuticals Llc |
Neue amide derivate und deren pharmazeutische verwendungen
|
US7696244B2
(en)
|
2003-05-16 |
2010-04-13 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
|
WO2004111014A1
(en)
|
2003-06-06 |
2004-12-23 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as modulators of atp-binding cassette transporters
|
EP1638505B1
(en)
|
2003-06-27 |
2012-04-25 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Amphiphilic pyridinium compounds, method of making and use thereof
|
US20050113576A1
(en)
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US7834008B2
(en)
|
2003-08-15 |
2010-11-16 |
H. Lundbeck A/S |
Cyclopropyl derivatives as NK3 receptor antagonists
|
WO2005026137A2
(en)
|
2003-09-06 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US20050070718A1
(en)
|
2003-09-30 |
2005-03-31 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
JP2007509044A
(ja)
|
2003-10-08 |
2007-04-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
シクロアルキルピラニル基を含むatp結合カセットトランスポーターのモジュレータ
|
TW200522964A
(en)
|
2003-10-16 |
2005-07-16 |
Sankyo Co |
5-aryl-pyrimidine derivatives
|
EP1679309A4
(en)
|
2003-10-24 |
2007-03-28 |
Ono Pharmaceutical Co |
ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
|
US7407976B2
(en)
|
2003-11-14 |
2008-08-05 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
WO2005075435A1
(en)
|
2004-01-30 |
2005-08-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
NZ548256A
(en)
|
2004-02-02 |
2010-02-26 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
EP1740532A4
(en)
|
2004-03-30 |
2009-06-10 |
Univ California |
CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
|
US20050222271A1
(en)
|
2004-03-31 |
2005-10-06 |
Le Huang |
Novel amorphous form of memantine hydrochloride
|
FR2868417B1
(fr)
|
2004-04-02 |
2006-06-23 |
Rhodia Chimie Sa |
Procede de formation d'une liaison carbone-carbone
|
EP1766062A4
(en)
|
2004-06-01 |
2008-07-09 |
Tm Bioscience Corp |
METHOD FOR DETECTING MUTATIONS ASSOCIATED WITH CYSTIC FIBROSIS
|
CA2569402A1
(en)
|
2004-06-04 |
2005-12-22 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
|
NZ587551A
(en)
|
2004-06-24 |
2012-01-12 |
Vertex Pharma |
5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
GB0416730D0
(en)
|
2004-07-27 |
2004-09-01 |
Novartis Ag |
Organic compounds
|
CN1993339B
(zh)
|
2004-08-06 |
2013-05-22 |
大塚制药株式会社 |
芳香化合物
|
DE102004047254A1
(de)
|
2004-09-29 |
2006-04-13 |
Merck Patent Gmbh |
Carbonylverbindungen
|
MX2007004484A
(es)
|
2004-10-13 |
2007-06-25 |
Ptc Therapeutics Inc |
Compuestos de pirazol o triazol y su uso para la fabricacion de un medicamento para tratar las enfermedades relacionadas con la mutacion somatica.
|
US7662910B2
(en)
|
2004-10-20 |
2010-02-16 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
JPWO2006057448A1
(ja)
|
2004-11-26 |
2008-06-05 |
武田薬品工業株式会社 |
アリールアルカン酸誘導体
|
EP1676834A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Sanofi-Aventis Deutschland GmbH |
Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
|
RU2416601C2
(ru)
|
2005-02-25 |
2011-04-20 |
Оно Фармасьютикал Ко., Лтд. |
Соединение индола и его применение
|
WO2006099256A2
(en)
|
2005-03-11 |
2006-09-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
JP2008538107A
(ja)
|
2005-03-18 |
2008-10-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異型cftrプロセシングの修正において活性を有する化合物及びその用途
|
US7297700B2
(en)
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
GB0506133D0
(en)
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
US20100120789A1
(en)
|
2005-03-24 |
2010-05-13 |
Nigel Vicker |
Compound
|
PL2248809T3
(pl)
|
2005-03-28 |
2012-10-31 |
Toyama Chemical Co Ltd |
3-[2-(Benzo[b]tiofen-5-ylo)-etoksy]-propaniany alkilu jako związki pośrednie w wytwarzaniu pochodnych azetydyn-3-olu
|
JP2006282534A
(ja)
|
2005-03-31 |
2006-10-19 |
Fuji Photo Film Co Ltd |
アミド類の製造方法
|
PT2402002T
(pt)
|
2005-04-08 |
2018-10-08 |
Ptc Therapeutics Inc |
Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
|
US20070032475A1
(en)
|
2005-04-15 |
2007-02-08 |
Ye Xiaocong M |
Novel compounds useful for bradykinin B1 receptor antagonism
|
AU2006251624A1
(en)
|
2005-05-24 |
2006-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding cassette transporters
|
CN101287732A
(zh)
|
2005-08-11 |
2008-10-15 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜电导调节剂的调控剂
|
AU2006279810B2
(en)
|
2005-08-11 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CN101272767B
(zh)
|
2005-08-29 |
2012-08-29 |
赛诺菲-安万特美国有限责任公司 |
7-氯-N,N,5-三甲基-4-氧-3-苯基-3,5-二氢-4H-哒嗪并[4,5-b]吲哚-1-乙酰胺的无定形固体分散体
|
CN101312722A
(zh)
|
2005-10-06 |
2008-11-26 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
WO2007056143A2
(en)
|
2005-11-02 |
2007-05-18 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
KR20150041174A
(ko)
|
2005-11-08 |
2015-04-15 |
버텍스 파마슈티칼스 인코포레이티드 |
Atp 결합 카세트 수송체의 헤테로사이클릭 조정제
|
GB0525144D0
(en)
|
2005-12-09 |
2006-01-18 |
Novartis Ag |
Organic compounds
|
RS55630B1
(sr)
|
2005-12-21 |
2017-06-30 |
Janssen Pharmaceutica Nv |
Triazolopiridazini kao modulatori tirozin kinaze
|
CN101374849A
(zh)
|
2005-12-24 |
2009-02-25 |
沃泰克斯药物股份有限公司 |
作为abc转运蛋白调控剂的喹啉-4-酮衍生物
|
WO2007075946A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
SI3219705T1
(sl)
|
2005-12-28 |
2020-08-31 |
Vertex Pharmaceuticals Incorporated |
Farmacevtski sestavki amorfne oblike N-(2,4-bis(1,1-dimetiletil)-5- hidroksifenil)-1,4-dihidro-4-oksokinolin-3-karboksamid
|
CN101395147B
(zh)
|
2005-12-28 |
2013-05-29 |
弗特克斯药品有限公司 |
作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
TW200808723A
(en)
|
2006-03-13 |
2008-02-16 |
Univ California |
Conformationally restricted urea inhibitors of soluble epoxide hydrolase
|
US20070218138A1
(en)
|
2006-03-20 |
2007-09-20 |
Bittorf Kevin J |
Pharmaceutical Compositions
|
KR20140107691A
(ko)
|
2006-03-20 |
2014-09-04 |
버텍스 파마슈티칼스 인코포레이티드 |
의약 조성물
|
WO2007111994A2
(en)
|
2006-03-22 |
2007-10-04 |
Syndexa Pharmaceuticals Corporation |
Compounds and methods for treatment of disorders associated with er stress
|
RU2462246C2
(ru)
*
|
2006-03-30 |
2012-09-27 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2869945C
(en)
|
2006-04-07 |
2018-01-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
JP2009536969A
(ja)
|
2006-05-12 |
2009-10-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミド組成物
|
AU2007257959A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
WO2008020227A2
(en)
|
2006-08-17 |
2008-02-21 |
Astrazeneca Ab |
Antibacterial pyrrolecarboxamides
|
WO2008029168A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
WO2008029152A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
AU2007309237B2
(en)
|
2006-10-23 |
2012-03-22 |
Sgx Pharmaceuticals, Inc. |
Triazolo-pyridazine protein kinase modulators
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
EP2118103B1
(en)
|
2006-11-03 |
2014-04-23 |
Vertex Pharmaceuticals Inc. |
Azaindole derivatives as cftr modulators
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
WO2008064259A2
(en)
|
2006-11-21 |
2008-05-29 |
Biokey, Inc. |
Solid dispersion composition comprising fluvastatin
|
WO2008065732A1
(fr)
|
2006-11-27 |
2008-06-05 |
Nippon Polyurethane Industry Co., Ltd. |
Procédé de production d'un mélange à base d'isocyanate modifié contenant une liaison allophanate et une liaison isocyanurate
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
AU2008251504B2
(en)
|
2007-05-09 |
2013-07-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
WO2008147952A1
(en)
|
2007-05-25 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
JP2010531304A
(ja)
|
2007-06-18 |
2010-09-24 |
ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド |
抗悪性腫瘍活性を有するpfkfb3阻害物質ファミリー
|
US8557823B2
(en)
|
2007-06-18 |
2013-10-15 |
Advanced Cancer Therapeutics, Llc |
Family of PFKFB3 inhibitors with anti-neoplastic activities
|
DK2178865T3
(en)
|
2007-07-19 |
2015-10-19 |
Lundbeck H As |
5-membered heterocyclic amides and related compounds
|
US20110177999A1
(en)
|
2007-08-09 |
2011-07-21 |
Vertex Pharmaceuticals Incorporated |
Therapeutic Combinations Useful in Treating CFTR Related Diseases
|
ES2578735T3
(es)
|
2007-08-24 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística
|
AU2008301907B2
(en)
|
2007-09-14 |
2014-02-20 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
CN101821266B
(zh)
|
2007-09-14 |
2014-03-12 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜通道调节因子的调节剂
|
RU2501787C2
(ru)
|
2007-11-02 |
2013-12-20 |
Метилджен Инк. |
Ингибиторы гистондеацетилазы
|
DK2217572T3
(da)
|
2007-11-16 |
2014-02-03 |
Vertex Pharma |
Isoquinoliner som modulatorer af ATP-bindingskassettetransportører
|
CA2706536C
(en)
|
2007-11-22 |
2016-04-19 |
Tadaaki Sugama |
Amorphous form of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
EP3170818B1
(en)
|
2007-12-07 |
2020-02-19 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
DK2639224T3
(en)
|
2007-12-07 |
2016-10-17 |
Vertex Pharma |
A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
|
BRPI0820681A2
(pt)
|
2007-12-07 |
2019-09-24 |
Vertex Pharma |
formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
|
CN101925603B
(zh)
|
2007-12-13 |
2013-12-04 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜通道调节因子的调节剂
|
WO2009086426A2
(en)
|
2007-12-28 |
2009-07-09 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
|
WO2009108657A2
(en)
|
2008-02-28 |
2009-09-03 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as cftr modulators
|
EP2271621B1
(en)
|
2008-03-31 |
2013-11-20 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as cftr modulators
|
WO2009127822A2
(en)
|
2008-04-16 |
2009-10-22 |
Biolipox Ab |
Bis-aryl compounds for use as medicaments
|
WO2009129501A1
(en)
|
2008-04-18 |
2009-10-22 |
Arete Therapeutics, Inc. |
Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
|
EA021758B1
(ru)
|
2008-04-24 |
2015-08-31 |
Бристол-Маерс Сквибб Компани |
Способ лечения болезни альцгеймера
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
US9447049B2
(en)
|
2010-03-01 |
2016-09-20 |
University Of Tennessee Research Foundation |
Compounds for treatment of cancer
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
CN102231990B
(zh)
|
2008-08-13 |
2013-09-25 |
沃泰克斯药物股份有限公司 |
N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
US8895781B2
(en)
|
2008-09-04 |
2014-11-25 |
Georgetown University |
Transition metal-catalyzed C—H amination using unactivated amines
|
TW201011009A
(en)
|
2008-09-15 |
2010-03-16 |
Priaxon Ag |
Novel pyrrolidin-2-ones
|
CA2736545A1
(en)
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
US20110257223A1
(en)
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
PT2358680E
(pt)
|
2008-10-23 |
2013-05-14 |
Vertex Pharma |
Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
|
AR074060A1
(es)
|
2008-10-23 |
2010-12-22 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
|
US8314239B2
(en)
|
2008-10-23 |
2012-11-20 |
Vertex Pharmaceutical Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
KR101587389B1
(ko)
|
2008-11-06 |
2016-01-28 |
버텍스 파마슈티칼스 인코포레이티드 |
Atp-결합 카세트 수송자의 조절자
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
AR074231A1
(es)
|
2008-11-27 |
2010-12-29 |
Boehringer Ingelheim Int |
Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos.
|
NZ593806A
(en)
|
2008-12-03 |
2014-04-30 |
Presidio Pharmaceuticals Inc |
Inhibitors of hcv ns5a
|
WO2010078103A1
(en)
|
2008-12-30 |
2010-07-08 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US8946419B2
(en)
|
2009-02-23 |
2015-02-03 |
Mallinckrodt Llc |
(+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
|
KR20100101055A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동 관련 질환의 치료 또는 예방용 약학적 조성물
|
ES2683633T3
(es)
|
2009-03-20 |
2018-09-27 |
Vertex Pharmaceuticals Incorporated |
Moduladores de regulador de conductancia transmembrana de la fibrosis quística
|
RU2543714C2
(ru)
|
2009-03-20 |
2015-03-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
|
GB0905641D0
(en)
|
2009-04-01 |
2009-05-13 |
Serodus As |
Compounds
|
ES2475091T3
(es)
|
2009-04-16 |
2014-07-10 |
Centro Nacional De Investigaciones Oncol�Gicas (Cnio) |
Imidazopirazinas como inhibidores de proteína cinasas
|
WO2011005355A1
(en)
|
2009-05-07 |
2011-01-13 |
Achaogen, Inc. |
Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
|
CN105130957A
(zh)
|
2009-05-29 |
2015-12-09 |
拉夸里亚创药株式会社 |
作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
|
EP2264012A1
(de)
|
2009-06-03 |
2010-12-22 |
Bayer CropScience AG |
Heteroarylamidine und deren Verwendung als Fungizide
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
WO2011029832A1
(de)
|
2009-09-09 |
2011-03-17 |
Vifor (International) Ag |
Neue thiazol- und oxazol-hepcidin-antagonisten
|
KR20120083416A
(ko)
|
2009-09-17 |
2012-07-25 |
버텍스 파마슈티칼스 인코포레이티드 |
아자비시클릭 화합물의 제조 방법
|
SG179112A1
(en)
|
2009-09-18 |
2012-04-27 |
Univ Nanyang Tech |
Process of forming an amide
|
EP2813227A1
(en)
|
2009-10-22 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
US8389727B2
(en)
|
2009-10-23 |
2013-03-05 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide
|
RU2553989C2
(ru)
|
2009-10-23 |
2015-06-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011109059A1
(en)
|
2010-03-01 |
2011-09-09 |
Gtx, Inc. |
Compounds for treatment of cancer
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
US8471029B2
(en)
|
2010-03-19 |
2013-06-25 |
Vertex Pharmaceutical Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
PL3835297T3
(pl)
*
|
2010-03-25 |
2023-09-11 |
Vertex Pharmaceuticals Incorporated |
Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
|
HUE056525T2
(hu)
|
2010-04-07 |
2022-02-28 |
Vertex Pharma |
3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
|
CN105037334A
(zh)
|
2010-04-07 |
2015-11-11 |
弗特克斯药品有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式
|
MX2012012204A
(es)
|
2010-04-22 |
2012-12-05 |
Vertex Pharma |
Proceso para producir compuestos de cicloalquilcarboxamido-indol.
|
EP2560651A1
(en)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
CA2796642A1
(en)
*
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
NZ603043A
(en)
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
EP2386606B1
(fr)
|
2010-04-30 |
2018-03-21 |
Total Marketing Services |
Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques
|
TW201202250A
(en)
|
2010-05-20 |
2012-01-16 |
Vertex Pharma |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
PL2571506T3
(pl)
|
2010-05-20 |
2017-10-31 |
Cempra Pharmaceuticals Inc |
Sposoby sporządzania makrolidów i ketolidów oraz ich produktów pośrednich
|
AU2011255237A1
(en)
|
2010-05-20 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
US20120149708A1
(en)
|
2010-06-17 |
2012-06-14 |
George Mason University |
Modulators of viral transcription, and methods and compositions therewith
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
UA110113C2
(xx)
|
2010-07-29 |
2015-11-25 |
|
Біциклічні азагетероциклічні карбоксаміди
|
MX2013002035A
(es)
|
2010-08-23 |
2013-03-25 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2, 2-difluorobenzo[d] [1, 3]dioxol-5-il)-n-(1-(2, 3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2 -metilpropano-2-il)-1h-indol-5-il) ciclopropanocarboxamida y administracion de las mismas.
|
EP2608775A2
(en)
|
2010-08-27 |
2013-07-03 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
WO2012049555A1
(en)
|
2010-10-13 |
2012-04-19 |
Lupin Limited |
Spirocyclic compounds as voltage-gated sodium channel modulators
|
WO2012052540A1
(en)
|
2010-10-21 |
2012-04-26 |
Universitaet Des Saarlandes |
Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
WO2012079583A1
(en)
|
2010-12-15 |
2012-06-21 |
Aarhus Universitet |
System providing controlled delivery of gaseous co for carbonylation reactions
|
US9295754B2
(en)
|
2011-02-24 |
2016-03-29 |
Emory University |
Noggin inhibitory compositions for ossification and methods related thereto
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
CN102731492B
(zh)
|
2011-03-30 |
2016-06-29 |
江苏恒瑞医药股份有限公司 |
环己烷类衍生物、其制备方法及其在医药上的应用
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
WO2013005057A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
New compounds
|
TWI700268B
(zh)
|
2011-09-09 |
2020-08-01 |
美商藍瑟斯醫學影像公司 |
用於合成及使用造影劑之組合物、方法及系統
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
CA2853299A1
(en)
|
2011-11-02 |
2013-05-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) for treating cftr mediated diseases
|
US20140127901A1
(en)
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
IN2014KN00885A
(pt)
|
2011-11-08 |
2015-10-02 |
Vertex Pharma |
|
WO2013086131A1
(en)
|
2011-12-06 |
2013-06-13 |
The Trustees Of The University Of Pennsylvania |
Inhibitors targeting drug-resistant influenza a
|
US8772541B2
(en)
|
2011-12-15 |
2014-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
|
EP2606726A1
(de)
|
2011-12-21 |
2013-06-26 |
Bayer CropScience AG |
N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
|
SI2806859T1
(sl)
|
2012-01-25 |
2019-11-29 |
Vertex Pharma |
Formulacije 3-(6-(1-(2.2-difluorobenzo(d)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
|
BR112014021090B1
(pt)
|
2012-02-27 |
2023-01-24 |
Vertex Pharmaceuticals Incorporated |
Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
|
WO2013151739A1
(en)
|
2012-04-03 |
2013-10-10 |
3M Innovative Properties Company |
Crosslinkable composition comprising photobase generators
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US20130284054A1
(en)
|
2012-04-26 |
2013-10-31 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
US9528016B2
(en)
|
2012-04-26 |
2016-12-27 |
Xerox Corporation |
Phase change inks comprising crystalline amides
|
CA2813472A1
(en)
|
2012-04-26 |
2013-10-26 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
US9228101B2
(en)
|
2012-04-26 |
2016-01-05 |
Xerox Corporation |
Rapidly crystallizing phase change inks and methods for forming the same
|
US8888905B2
(en)
|
2012-04-26 |
2014-11-18 |
Xerox Corporation |
Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
|
WO2013174757A1
(en)
|
2012-05-25 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof
|
GB2502624A
(en)
|
2012-06-01 |
2013-12-04 |
Univ East Anglia |
Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
|
WO2013184198A1
(en)
|
2012-06-08 |
2013-12-12 |
Massachusetts Institute Of Technology |
Phosphine-ligated palladium sulfonate palladacycles
|
WO2013185112A1
(en)
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Pharmaceuticl compositions for the treatment of cftr -mediated disorders
|
FR2992317B1
(fr)
|
2012-06-22 |
2016-05-13 |
Diverchim |
Procede de preparation de peptides chiraux
|
WO2014002106A1
(en)
|
2012-06-25 |
2014-01-03 |
Cadila Healthcare Limited |
Novel compounds for the treatment of dyslipidemia and related diseases
|
DK3103872T3
(en)
|
2012-07-12 |
2018-10-22 |
Proqr Therapeutics Ii Bv |
OLIGONUCLEOTIDES TO MAKE A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE IN A LIVING CELL
|
WO2014011050A1
(en)
|
2012-07-12 |
2014-01-16 |
Proqr Therapeutics B.V. |
Exon replacement with stabilized artificial rnas
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
US10207989B2
(en)
|
2012-09-20 |
2019-02-19 |
Temple University—Of the Commonwealth System of Higher Education |
Substituted alkyl diaryl derivatives, methods of preparation and uses
|
BR102012025405A2
(pt)
|
2012-10-05 |
2014-10-07 |
Univ Brasilia Fudacao |
Processo de obtenção de amidas via aminólise catalítica de ésteres e ácidos carboxílicos em líquidos iônicos
|
KR101677866B1
(ko)
|
2012-10-29 |
2016-11-18 |
코니카 미놀타 가부시키가이샤 |
위상차 필름, 원편광판 및 화상 표시 장치
|
SI2914248T2
(sl)
|
2012-11-02 |
2023-12-29 |
Vertex Pharmaceuticals Incorporated, |
Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje CFTR
|
EP2919770A4
(en)
|
2012-11-14 |
2017-03-08 |
The Board of Regents of The University of Texas System |
Inhibition of hif-2 heterodimerization with hif1 (arnt)
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたcftr増強物質
|
WO2014081697A2
(en)
|
2012-11-20 |
2014-05-30 |
Merial Limited |
Anthelmintic compounds and compositions and method of using thereof
|
ITMI20122065A1
(it)
|
2012-12-03 |
2014-06-04 |
Univ Padova |
Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
|
US20150346185A1
(en)
|
2012-12-05 |
2015-12-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Diagnosis of cystic fibrosis
|
EP2928532A4
(en)
|
2012-12-07 |
2016-06-29 |
Parion Sciences Inc |
NOSE CANNULA FOR THE ADMINISTRATION OF MEDICAMENTS IN AEROSOL FORM
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
US9382254B2
(en)
|
2013-05-07 |
2016-07-05 |
Galapagos Nv |
Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
|
AU2014268477A1
(en)
|
2013-05-24 |
2015-11-12 |
The California Institute For Biomedical Research |
Compounds for treatment of drug resistant and persistent tuberculosis
|
JP2014232188A
(ja)
|
2013-05-29 |
2014-12-11 |
コニカミノルタ株式会社 |
セルロースアシレートフィルム、円偏光板及び画像表示装置
|
US20160151335A1
(en)
|
2013-06-26 |
2016-06-02 |
Proteostasis Therapeutics, Inc. |
Methods of modulating cftr activity
|
MY176814A
(en)
|
2013-08-08 |
2020-08-21 |
Galapagos Nv |
Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
|
US9688990B2
(en)
|
2013-09-12 |
2017-06-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
CA2924527C
(en)
|
2013-09-20 |
2022-07-12 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Compounds for treating prostate cancer
|
US9353078B2
(en)
|
2013-10-01 |
2016-05-31 |
New York University |
Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
|
US9700881B2
(en)
|
2013-10-09 |
2017-07-11 |
Emory University |
Heterocyclic coupling catalysts and methods related thereto
|
US10231932B2
(en)
|
2013-11-12 |
2019-03-19 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
|
KR20150062652A
(ko)
|
2013-11-29 |
2015-06-08 |
삼성전자주식회사 |
초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법
|
WO2015103317A1
(en)
|
2013-12-30 |
2015-07-09 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
US20170029366A1
(en)
|
2014-03-07 |
2017-02-02 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
JP2015172005A
(ja)
|
2014-03-11 |
2015-10-01 |
国立大学法人 東京大学 |
鉄触媒によるカップリング化合物の製造方法
|
AU2015229188A1
(en)
|
2014-03-13 |
2016-09-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
WO2015138934A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
CN110840847B
(zh)
|
2014-04-15 |
2022-07-29 |
沃泰克斯药物股份有限公司 |
用于治疗囊性纤维化跨膜传导调节因子介导的疾病的药物组合物
|
EP3139949B1
(en)
|
2014-05-08 |
2020-07-29 |
Phasebio Pharmaceuticals, Inc. |
Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
|
RU2688191C2
(ru)
|
2014-05-12 |
2019-05-21 |
ВЕРОНА ФАРМА ПиэЛСи |
Новое лечение
|
SI3142637T1
(sl)
|
2014-05-16 |
2021-01-29 |
Olaplex, Inc. |
Zdravilne formulacije keratina in postopki
|
EP3145925B1
(en)
|
2014-05-19 |
2020-11-04 |
Boehringer Ingelheim Animal Health USA Inc. |
Anthelmintic compounds
|
CA2948888A1
(en)
|
2014-06-05 |
2015-12-10 |
Merck Patent Gmbh |
Novel quinoline derivatives and their use in neurodegenerative diseases
|
WO2015196071A1
(en)
|
2014-06-19 |
2015-12-23 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
CN107105749A
(zh)
|
2014-08-13 |
2017-08-29 |
阿克索生物医药公司 |
抗微生物化合物和组合物及其用途
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
SG11201701598PA
(en)
|
2014-09-10 |
2017-03-30 |
Epizyme Inc |
Smyd inhibitors
|
WO2016050210A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种多官能化聚乙二醇衍生物及其制备方法
|
WO2016050209A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种异官能化聚乙二醇衍生物、制备方法及其生物相关物质
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
WO2016050208A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种多官能化聚乙二醇衍生物修饰的生物相关物质
|
WO2016054560A1
(en)
|
2014-10-02 |
2016-04-07 |
Flatley Discovery Lab |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
HUE051972T2
(hu)
|
2014-10-06 |
2021-04-28 |
Vertex Pharma |
Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai
|
BR112017007072A2
(pt)
|
2014-10-06 |
2018-01-30 |
Flatley Discovery Lab Llc |
compostos de triazolopiridina e métodos para o tratamento de fibrose cística
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
WO2016057811A1
(en)
|
2014-10-08 |
2016-04-14 |
Nivalis Therapeutics, Inc. |
Methods for the treatment of cystic fibrosis
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
EP3212201B1
(en)
|
2014-10-28 |
2022-10-19 |
BCI Pharma |
Nucleoside kinase inhibitors
|
KR20230040378A
(ko)
|
2014-10-31 |
2023-03-22 |
애브비 에스.에이.알.엘. |
치환된 크로만 및 이의 사용 방법
|
MX2017005663A
(es)
|
2014-10-31 |
2018-03-01 |
Abbvie Sarl |
Tetrahidropiranos sustituidos y metodo de uso.
|
DK3221692T3
(da)
|
2014-11-18 |
2021-08-23 |
Vertex Pharma |
Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
|
WO2016086015A1
(en)
|
2014-11-25 |
2016-06-02 |
University Of Rochester |
Myoglobin-based catalysts for carbene transfer reactions
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
WO2016105484A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
US10392378B2
(en)
|
2014-12-23 |
2019-08-27 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
AU2015370463B2
(en)
|
2014-12-24 |
2020-12-24 |
Kither Biotech S.R.L. |
Novel PI3K gamma inhibitor peptide for treatment of respiratory system diseases
|
WO2016109362A1
(en)
|
2014-12-31 |
2016-07-07 |
Auspex Pharmaceuticals, Inc. |
Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
|
CN105753814A
(zh)
|
2015-01-01 |
2016-07-13 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
US10196384B2
(en)
|
2015-03-31 |
2019-02-05 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR modulators
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|